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Cytoplasmic dynein is a minus-end-directed microtubule-based motor that
acts at diverse subcellular sites. During mitosis, dynein localizes simul-
taneously to the mitotic spindle, spindle poles, kinetochores and the cell
cortex. However, it is unclear what controls the relative targeting of
dynein to these locations. As dynein is heavily post-translationally modi-
fied, we sought to test a role for these modifications in regulating dynein
localization. We find that dynein rapidly and strongly accumulates at mito-
tic spindle poles following treatment with NSC697923, a small molecule
that inhibits the ubiquitin E2 enzyme, Ubc13, or treatment with PYR-41,
a ubiquitin E1 inhibitor. Subsets of dynein regulators such as Lis1, ZW10
and Spindly accumulate at the spindle poles, whereas others do not,
suggesting that NSC697923 differentially affects specific dynein popu-
lations. We additionally find that dynein relocalization induced by
NSC697923 or PYR-41 can be suppressed by simultaneous treatment with
the non-selective deubiquitinase inhibitor, PR-619. However, we did not
observe altered dynein localization following treatment with the selective
E1 inhibitor, TAK-243. Although it is possible that off-target effects of
NSC697923 and PYR-41 are responsible for the observed changes in
dynein localization, the rapid relocalization upon drug treatment highlights
the highly dynamic nature of dynein regulation during mitosis.1. Introduction
Dynein is a AAAþ ATPase that uses the energy from ATP hydrolysis to walk
along a microtubule [1]. Dynein localizes to diverse sites within the cell,
including the mitotic spindle, the centrosomes, the nuclear envelope, the kine-
tochores and the cell cortex, where it performs numerous roles in interphase
and mitosis [2]. This subcellular targeting is accomplished in part by the
association of the dynein complex with various regulatory and adaptor pro-
teins, including the dynactin complex, NuMA, Spindly, Bicaudal D2, Nde1
(also known as NudE) and others [3].
Dynein is also heavily post-translationallymodified [4], suggesting thepresence
of additional mechanisms for regulating its localization and function. For example,
multiple sites within dynein are modified by ubiquitin [4–11]. The most well-
characterized function of ubiquitination is to target a substrate for degradation
by the 26S proteasome [12], but ubiquitination also plays non-degradative roles
in regulating diverse processes such as endocytosis and DNA repair [13,14].
Additionally, protein–protein interactions and localization can be regulated byubi-
quitination [15]. Prior work has identified several ubiquitination sites within the
dynein complex or dynein regulatory proteins that do not increase in abundance
upon proteasome inhibition [6], and therefore may alter dynein function through
non-degradative mechanisms. Indeed, evidence suggests that the dynein–NuMA
interaction is enhanced by non-degradative ubiquitination [16], and a role for
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2non-degradative ubiquitination has also been implicated in
indirectly targeting dynein to the cell cortex [17].
Ubiquitination is mediated by the sequential actions of
an E1 activating enzyme, an E2 conjugating enzyme and
an E3 ligase. Polyubiquitin chains can be built from any
of seven internal lysines or the N-terminal methionine of
ubiquitin [12]. The type of linkage used in building the
polyubiquitin chain helps to determine the downstream effect
on the ubiquitinated substrate [12]. For example, proteasome
targeting is typically directed by the synthesis of a lysine 48-
linked polyubiquitin chain [12], whereas a K63-linked chain
is the most abundant non-degradative ubiquitination event
[18]. The E2 enzymes typically specify the type of linkage gen-
erated, with Ubc13 acting as the primary ubiquitin E2 enzyme
involved in K63-linked non-degradative chain formation [13].
However, the cellular processes regulated by non-degradative
ubiquitination remain incompletely understood.
Here, we use a small molecule inhibitor of Ubc13, as well
as inhibitors targeting other components of the ubiquitin con-
jugation machinery to reveal the highly dynamic nature of
dynein localization in mitotic cells.2. Results
2.1. Dynein rapidly accumulates at the spindle poles
following Ubc13 inhibition by NSC697923
treatment
We hypothesized that post-translational modifications may
play a critical role in controlling the subcellular localization
of the cytoplasmic dynein complex. We therefore sought to
identify perturbations that alter dynein localization. To begin,
we treated HeLa cells stably expressing GFP-tagged dynein
heavy chain (DHC-GFP) with inhibitors of mitotic kinases
and phosphatases to perturb cellular phosphorylation. We
did not observe any obvious changes in the mitotic localization
of dynein following transient inhibition of Aurora kinases
(ZM447439/VX680), cyclin-dependent kinase (flavopiridol),
Mps1 (AZ3146), Plk1 (BI2536), PP1 or PP2A (okadaic acid)
(data not shown). We next tested for a contribution from ubi-
quitination to dynein localization by treating with the Ubc13
inhibitor, NSC697923 (figure 1a) [19]. After only 15 min of
treatment, NSC697923 caused a nearly complete disassembly
of the mitotic spindle in 23 of 100 mitotic cells analysed
(figure 1b). Strikingly, in the majority of cells with spindle
microtubules remaining, we observed a dramatic accumu-
lation of dynein at two foci that correspond to the spindle
poles (figure 1b). Treatment with a low dose of nocodazole
resulted in a similar disruption of the mitotic spindle, but
did not induce dynein accumulation at the spindle poles,
suggesting that the NSC697923-induced effects on dynein
localization are independent of its effects on the mitotic spin-
dle (figure 1c). To further test this, we stabilized the mitotic
spindle by treating cells with the microtubule-stabilizing
drug taxol. Taxol treatment alone did not alter the localiz-
ation of dynein (figure 1d ). We next simultaneously treated
cells with NSC697923 and taxol. Under these conditions,
the mitotic spindle was largely preserved and we again
observed strong dynein relocalization to the spindle poles
in 79+ 6% of cells in either prometaphase or metaphase,
compared with only 1+ 2% of cells treated with taxolalone (figure 1d; see also figure 6). Line scan analyses con-
firmed an increase in dynein intensity at the spindle poles
following NSC697923 treatment (electronic supplementary
material, figure S1A). This suggests that the change in
dynein localization is not a secondary consequence of dis-
rupting the structure of the mitotic spindle. Co-staining for
NuMA, one of the outermost proteins at the spindle pole
[20], revealed that NuMA localization is unaffected by
NSC697923 treatment (figure 1e; electronic supplementary
material, figure S1B) and that the spindle pole-localized
dynein was slightly internal to the localization of NuMA
(figure 1e). Together, our data demonstrate a rapid accumu-
lation of dynein at the spindle poles following the addition of
the small molecule inhibitor, NSC697923.2.2. A subset of dynein-associated factors accumulate
at spindle poles after NSC697923 treatment
Dynein heavy chain associates with numerous proteins,
including other subunits of the dynein complex, as well as
various adaptor proteins [3]. We therefore sought to deter-
mine which other proteins accumulate with dynein heavy
chain at the spindle poles after NSC697923 treatment. As
expected, another subunit of the dynein complex, the
dynein light chain Tctex-type 3, also accumulated at the mito-
tic spindle poles following NSC697923 addition (figure 2a).
By contrast, ARP1, a subunit of the dynactin complex and a
key regulator of dynein, strongly localizes to mitotic spindle
poles in untreated cells, with no obvious alteration in localiz-
ation following NSC697923 treatment (figure 2b). Next, we
examined Lis1 and Nde1, proteins that coordinately regulate
diverse functions of dynein [3,21]. Lis1 strongly accumulated
at the spindle poles following NSC697923 treatment during
prometaphase (figure 2c), whereas the localization of Nde1
was comparatively unaffected in both prometaphase and meta-
phase (figure 2d). Because only a subset of dynein-interacting
proteins relocalize to the spindle poles after NSC697923 treat-
ment, these data suggest that NSC697923 differentially affects
specific dynein complexes.
We next sought to test the localization of diverse mitotic
proteins following NSC697923 treatment. In addition to the
spindle pole-localized protein NuMA (figure 1e), we found
that the centriole and spindle-localized protein CSAP [22]
appeared unaffected by treatment with NSC697923 (figure 3a).
The centromere-localized protein, CENP-A, was similarly unaf-
fected by NSC697923 treatment (figure 3a). Thus, NSC697923
does not globally disrupt mitotic protein function.
The Rod/Zwilch/ZW10 (RZZ) complex and Spindly are
involved in targeting dynein to mitotic kinetochores [3] and
have been proposed to be cargo of the dynein complex [23].
In agreement with this, we found that ZW10 and Spindly
accumulated at the spindle poles after treatment with
NSC697923 (figure 3b,c). The RZZ complex also plays a key
role in targeting the spindle assembly checkpoint proteins,
MAD1 and MAD2, to mitotic kinetochores [24–26]. We
found that MAD1 clearly accumulates at the spindle poles
following NSC697923 treatment (figure 3d ). The behaviour
of MAD2 was more variable, but we typically saw some
localization of MAD2 at the spindle poles in NSC697923-
treated cells that we did not observe in control cells
(figure 3e). By contrast, the localization of Bub1, a key
protein involved in targeting the RZZ complex to mitotic
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Figure 1. NSC697923 induces accumulation of dynein at the mitotic spindle poles. (a) Cartoon of the ubiquitin conjugation pathway. NSC697923 is a small molecule
inhibitor of the ubiquitin E2 enzyme, Ubc13. (b–d) Immunofluorescence images of DNA (Hoechst), stably expressed dynein heavy chain-GFP (DHC-GFP), and micro-
tubules (DM1A) after treating the cells for 15 min with the indicated compounds. Scale bars, 10 mm; 1 mm in the magnified panel. (e) Representative
immunofluorescence images of stably expressed dynein heavy chain-GFP (DHC-GFP) and NuMA after treatment for 15 min with NSC697923 and taxol. Scale bar,
10 mm; 5 mm in the magnified panel.
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Figure 2. NSC697923 induces accumulation of a subset of dynein regulators at the mitotic spindle poles. (a) Representative immunofluorescence images of stably
expressed GFP-Tctex-type 3, microtubules (DM1A) and DNA (Hoechst) after treating the cells for 15 min with the indicated compounds. Scale bar, 10 mm.
(b) Representative immunofluorescence images of stably expressed GFP-ARP1, microtubules (DM1A), and DNA (Hoechst) after treating the cells for 15 min with
the indicated compounds. Scale bar, 10 mm. (c) Representative immunofluorescence images of stably expressed GFP-Lis1, microtubules (DM1A) and DNA (Hoechst)
after treating the cells for 15 min with the indicated compounds. Scale bar, 10 mm. (d ) Representative immunofluorescence images of stably expressed GFP-Nde1,
microtubules (DM1A) and DNA (Hoechst) after treating the cells for 15 min with the indicated compounds. Scale bar, 10 mm.
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4kinetochores [24,27], appeared unaffected by NSC697923
treatment (figure 3e). Together, these data define a subset
of dynein-interacting proteins that show altered localization
following treatment with NSC697923.2.3. Proteasome inhibition does not alter dynein
localization in mitosis
Although K63-linked polyubiquitination is not a canonical
signal for degradation, K63 chains can still alter substrate
stability [12]. To test whether the relocalization of dynein fol-
lowing NSC697923 treatment was due to altered protein
stability, we assessed dynein localization following inhibition
of the proteasome with MG132 (figure 4a). In contrast to the
relocalization induced by NSC697923 treatment, proteasome
inhibition did not induce an accumulation of dynein at spin-
dle poles (figure 4b). We also visualized endogenous ZW10 in
these cells by immunofluorescence and did not observe
signal that noticeably differed from DMSO-treated cells
(figure 4b). Proteasomal targeting is frequently accomplishedby K48-linked polyubiquitin chains, and Cdc34 is a key E2
enzyme involved in K48-linked polyubiquitin chain for-
mation [28]. We therefore also used CC0651 [29], an
inhibitor of Cdc34, and again did not observe a change in
dynein or ZW10 localization (figure 4b). Collectively, these
results suggest that the mitotic localization of dynein is not
regulated by a degradative ubiquitination event.2.4. Ubiquitin E1 inhibitors have differential effects
on dynein localization in mitosis
Ubiquitination requires the sequential activities of three dis-
tinct enzymes. The E2 enzymes, such as Ubc13, rely on an
upstream ubiquitin activation step performed by a ubiquitin
E1 enzyme. We therefore sought to further test whether the
relocalization of dynein induced by NSC697923 treatment is
due to inhibition of ubiquitination by treating cells with
PYR-41 [30] or TAK-243 [31], small molecule inhibitors that
target the E1 enzyme. As we observed for NSC697923 treat-
ment, PYR-41 rapidly induced the accumulation of dynein
(b)
D
N
A
m
ic
ro
tu
bu
le
s
G
FP
-Z
W
10
NSC697923 + taxoltaxol
prometaphase metaphase metaphaseprometaphase
(a) NSC697923 + taxoltaxol
D
N
A
prometaphase metaphase metaphaseprometaphase
G
FP
-C
EN
P-
A
G
FP
-C
SA
P
m
ic
ro
tu
bu
le
s
(e) NSC697923 + taxoltaxol
D
N
A
prometaphase metaphase metaphaseprometaphase
M
A
D
2
B
ub
1
(d) NSC697923 + taxoltaxol
prometaphase metaphase metaphaseprometaphase
D
N
A
M
A
D
1
(c) NSC697923 + taxoltaxol
prometaphase metaphase metaphaseprometaphase
D
N
A
Sp
in
dl
y
Figure 3. NSC697923 induces accumulation of a subset of dynein interactors at the mitotic spindle poles. (a) Representative immunofluorescence images of stably
expressed GFP-CENP-A and GFP-CSAP, microtubules (DM1A) and DNA (Hoechst) after treating the cells for 15 min with the indicated compounds. Scale bar, 10 mm.
(b) Representative immunofluorescence images of stably expressed GFP-ZW10, microtubules (DM1A) and DNA (Hoechst) after treating the cells for 15 min with the indi-
cated compounds. Scale bar, 10 mm. (c) Representative immunofluorescence images of Spindly and DNA (Hoechst) after treating the cells for 15 min with the indicated
compounds. Scale bar, 10 mm. (d ) Representative immunofluorescence images of MAD1 and DNA (Hoechst) after treating the cells for 15 min with the indicated com-
pounds. Scale bar, 10 mm. (e) Representative immunofluorescence images of MAD2, Bub1 and DNA (Hoechst) after treating the cells for 15 min with the indicated
compounds. Arrows indicate weak, but detectable localization of MAD2 at the spindle poles. Scale bar, 10 mm.
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5and ZW10 at spindle poles (figure 5a). Indeed, by live-cell
imaging, increased dynein levels were observed at poles
within 5 min of addition of PYR-41 in both the absence and
presence of taxol to stabilize the mitotic spindle (figure 5b).
However, the recently developed E1 inhibitor, TAK-243, did
not affect dynein localization (figure 5a). TAK-243 is a
potent inhibitor of both Uba1 and the other human ubiquitin
E1 enzyme, Uba6 [31]. Thus, the lack of dynein relocalization
following TAK-243 treatment suggests that the NSC697923and PYR-41-induced spindle pole accumulation of dynein
could be due to off-target effects. To test this possibility, we
used the TS20 cell line that contains temperature-sensitive
mutations in Uba1 [32,33], the primary ubiquitin E1
enzyme. At the restrictive temperature, Uba1 levels should
be significantly reduced, yet we did not observe an accumu-
lation of ZW10 at the spindle poles (figure 5c). Additionally,
in the absence of Uba1, the cells should be insensitive to any
on-target effects of PYR-41. However, we found that PYR-41
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Figure 4. Dynein localization is not controlled by degradative ubiquitination. (a) Cartoon of the ubiquitin conjugation pathway illustrating the ubiquitin E2 enzyme,
Cdc34, and the targeting of substrates for degradation by the 26S proteasome. CC0651 inhibits Cdc34 and MG132 inhibits the proteasome. (b) Representative
immunofluorescence images of stably expressed dynein heavy chain-GFP (DHC-GFP), ZW10, microtubules (DM1A) and DNA (Hoechst) after treating the cells for
15 min with the indicated compounds. Scale bar, 10 mm.
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6still induced ZW10 accumulation at the spindle poles at the
restrictive temperature (figure 5c). We were also unable to
validate the specificity of PYR-41 using a CRISPR/Cas9-
based system [34] to eliminate Uba1 from HeLa cells (data
not shown). Therefore, it is possible that the relocalization
of dynein induced by PYR-41 and NSC697923 is not due to
directly interfering with ubiquitination, but instead is
caused by off-target effects.2.5. NSC697923- and PYR-41-induced dynein
relocalization is suppressed by simultaneous
treatment with the deubiquitinase inhibitor
PR-619
If the PYR-41- and NSC697923-mediated effects on dynein
localization are due to inhibition of ubiquitination, wereasoned that inhibiting the deubiquitinases might also per-
turb the localization of dynein due to the dynamic balance
of ubiquitin conjugation. To test this premise, we assessed
the consequences of treating cells with the non-selective
deubiquitinase inhibitor, PR-619 (figure 6a). Addition of
PR-619 induced dynein accumulation at the spindle poles
in a smaller percentage of cells relative to NSC697923 or
PYR-41 treatment (figure 6b,c). However, when PR-619 was
simultaneously added to cells with either NSC697923 or
PYR-41, the percentage of cells exhibiting accumulated
dynein was reduced relative to NSC697923 or PYR-41 treat-
ment alone (figure 6b,c). Thus, PR-619 treatment appeared to
suppress the effects of NSC697923 and PYR-41 on dynein
localization. Similar trends were also observed for the reloca-
lization of ZW10 and MAD1 (figure 6d ). If the effects of
these compounds are on-target, these results suggest that
ubiquitination dynamics may be critical for controlling
dynein localization during mitosis. Inhibiting ubiquitination
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Figure 5. Dynein accumulation at the spindle poles is induced by PYR-41. (a) Top: Cartoon illustrating inhibition of the ubiquitin E1 enzyme by PYR-41 and TAK-
243. Bottom: Representative immunofluorescence images of stably expressed dynein heavy chain-GFP (DHC-GFP), ZW10, microtubules (DM1A) and DNA (Hoechst)
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9by NSC697923 or PYR-41 treatment may allow the counter-
acting deubiquitinases to dominate, thereby resulting in
rapid removal of ubiquitin from the substrate and ultimately
causing dynein to accumulate at the spindle poles.
Together, our observations that the mitotic localization of
dynein can be rapidly altered highlight the highly dynamic
nature of dynein regulation within the cell.blishing.org
Open
Biol.8:1800953. Discussion
As the primary minus-end-directed microtubule motor,
dynein is required for numerous cellular processes. Thus,
the localization and function of dynein must be precisely
regulated. For example, dynamic regulation of dynein localiz-
ation during mitosis is required for proper positioning of the
mitotic spindle within the cell during both metaphase and
anaphase [35,36]. Our work highlights that the localization
of dynein can be rapidly altered, as we observe a dramatic
change in the subcellular distribution of dynein within min-
utes of drug addition. The ability to quickly retarget dynein
to specific sites may allow the cell to dynamically respond
to changing needs in force generation or cargo transport.
NSC697923 and PYR-41 could alter dynein localization by
several possible mechanisms. First, as dynein is a minus-end-
directed motor and the microtubule minus ends are located
at the spindle poles, these inhibitors could stimulate dynein
motility. In support of this model, dynein relocalization is
not observed when the microtubules have been depolymerized
(figure 1c). A second, non-mutually exclusive mechanism
entails an enhanced interaction between dynein and a spindle
pole-localized protein due to modification of dynein, a dynein
regulator or a spindle-pole protein. This altered interaction
could recruit dynein complexes from the cytoplasm, or it
could trap dynein complexes that have arrived at the spindle
pole after walking along a microtubule. In fact, prior work
found that ATP depletion or NDGA treatment prevents the
release of dynein from spindle poles and thereby causes a simi-
lar accumulation at the poles [23,37–40], albeit with slower
kinetics than what we observed here.
Inhibitors targeting both ubiquitin E1 and E2 enzymes
cause an increase in dynein signal at spindle poles, suggesting
that dynein localization is regulated by ubiquitination. Indeed,
another inhibitor of Ubc13, BAY 11–7082 [41], similarly reloca-
lized dynein (data not shown). However, recent in vitro studies
demonstrated that BAY 11-7082 additionally inhibits the ubi-
quitin E1 enzyme [42]. As BAY 11-7082 shares structural
similarity with NSC697923, it is plausible that dynein relocali-
zation induced by NSC697923 is actually also due to inhibition
of the ubiquitin E1 enzyme. Alternatively, our observation that
TAK-243, a more potent [30,31] and presumably more specific
ubiquitin E1 inhibitor, does not cause the same alteration in
dynein localization suggests that there may be another cellular
target shared by both NSC697923 and PYR-41. Both PYR-41
and NSC697923 are known to have off-target effects. PYR-41
has been shown to non-specifically cross-link proteins [43]
and NSC697923 inhibits the activity of several deubiquitinases
in vitro [44]. Additionally, it is important to note that TAK-243
treatment does not obviously affect the mitotic spindle on
the time scales analysed here. By contrast, PYR-41 treatment
causes the spindle poles to move inwards towards the DNA
(figure 5b). As an inhibitor of the most upstream step in the
ubiquitination pathway, PYR-41 should inhibit almost allcellular ubiquitination. Thus, it is particularly surprising that
NSC697923 treatment, which should only inhibit the subset
of ubiquitination events catalysed by Ubc13, results in potent
disassembly of the mitotic spindle (figure 1b). Therefore, the
distinct microtubule phenotypes we observe after PYR-41 or
NSC697923 treatment may be further evidence of off-target
effects of one or both compounds.
Regardless of the precise mechanism used, the rapid relo-
calization of dynein following the addition of NSC697923
and PYR-41 indicates a highly dynamic and precise regulatory
network controlling dynein function.4. Experimental procedures
4.1. Molecular biology
GFP-tagged constructs for expression in human cells were
generated by cloning the human cDNA into a pBABEblast
vector containing an N-terminal LAP tag (GFP-TEV-S) as
described previously [45].
4.2. Cell culture and cell line generation
HeLa cells were cultured in Dulbecco’s modified Eagle
medium supplemented with 10% fetal bovine serum (GE
Healthcare), 100 units ml21 penicillin, 100 units ml–1 strepto-
mycin and 2 mM L-glutamine at 378C with 5% CO2. TS20
cells were cultured in Dulbecco’s modified Eagle medium
supplemented with 10% fetal bovine serum (GE Healthcare),
2 mM L-glutamine and MEM Non-essential amino acids at
358C with 5% CO2.
HeLa cells expressing mouse DHC–GFP were obtained
from MitoCheck [46]. HeLa cells expressing GFP-tagged
Tctex-type3, ARP1, Lis1, Nde1, CENP-A and CSAP were
generated by retroviral infection followed by Blasticidin selec-
tion and single-cell sorting. HeLa cells expressing GFP-ZW10
were a gift from Geert Kops (Hubrecht Institute). TS20 cells
are a BALB/3T3 cell line containing a temperature-sensitive
mutation in the ubiquitin E1 enzyme, Uba1, and were a gift
from Nianli Sang (Drexel University). For experiments at
the restrictive temperature, TS20 cells were cultured at 398C
for 8 h before treating with PYR-41 for 15 min and then
fixing for immunofluorescence.
4.3. Chemicals
All chemicals were resuspended in DMSO. NSC697923
(Sigma-Aldrich) was used at 20 mM. Nocodazole (Sigma-
Aldrich) was used at 50 nM. MG132 (EMD Biosciences) was
used at 10 mM. CC0651 (Thermo Fisher Scientific) was used
at 50 mM. Taxol (Life Technologies) was used at 1 mM. PYR-
41 (Santa Cruz Biotechnology) was used at 20 mM. TAK-243
(formerly MLN7243) was a gift from Hidde Ploegh (White-
head Institute) and used at 25 mM. PR-619 (Sigma-Aldrich)
was used at 100 mM. ZM447439 (R&D Systems) was used at
2 mM. VX680 (LC Laboratories) was used at 2.5 mM. Flavopir-
idol (Santa Cruz Biotechnology) was used at 5 mM. AZ3146
(Tocris) was used at 2 mM. BI2536 (Thermo Fisher Scientific)
was used at 10 mM. Okadaic acid (VWR) was used at 1 mM.
To dose cells, drugs were diluted in fresh media and then
added to the cells. For immunofluorescence, cells were dosed
for 15 min before fixation.
rsob.royalsocietypublishing.org
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104.4. Immunofluorescence
Cells were plated on glass coverslips coated with poly-L-lysine
(Sigma-Aldrich). Cells were fixed with 4% formaldehyde in
PHEM buffer (60 mM PIPES, 25 mM HEPES, 10 mM EGTA
and 4 mM MgSO4, pH 7) for 10 min. Blocking and all anti-
body dilutions were performed using AbDil (20 mM Tris,
150 mM NaCl, 0.1% Triton X-100, 3% BSA and 0.1% NaN3,
pH 7.5). PBS plus 0.1% Triton X-100 (PBS-TX) was used for
washes. GFP-Booster (Chromotek; 1 : 200 dilution) was used
to amplify the fluorescence of the GFP-tagged transgenes.
DM1A was used to stain the microtubules (Sigma-Aldrich;
1 : 3000 dilution). For staining of NuMA, ab36999 (Abcam)
was used at a 1 : 500 dilution. For staining of Spindly, rabbit
anti-Spindly [47] (a gift from Erich Nigg and Anna Santa-
maria, Max Planck Institute of Biochemistry) was used at a
1 : 1000 dilution. For staining of MAD1, ab5783 (Abcam) was
used at a 1 : 1000 dilution. For staining of MAD2, A300-301A
(Bethyl Laboratories) was used at 1 mg ml21. For staining
of Bub1, ab54893 (Abcam) was used at a 1 : 500 dilution. For
staining of ZW10, ab21582 (Abcam) was used at 1 mg ml21.
Cy3- and Cy5-conjugated secondary antibodies (Jackson
ImmunoResearch Laboratories) were used at a 1 : 300 dilution.
DNAwas visualized by incubating cells in 1 mg ml21 Hoechst-
33342 (Sigma-Aldrich) in PBS-TX for 10 min. Coverslips were
mounted using PPDM (0.5% p-phenylenediamine and
20 mM Tris-Cl, pH 8.8, in 90% glycerol).
4.5. Fluorescence microscopy
Images were acquired on a DeltaVision Core microscope
(Applied Precision) equipped with a CoolSnap HQ2 CCD
camera (Photometrics). A 100, 1.4NA U-PlanApo objective(Olympus) was used to image fixed cells, and a 60, 1.42NA
Plan Apo N objective (Olympus) was used for live-cell ima-
ging. Images were deconvolved and maximally projected.
The fluorescence is not scaled equivalently in each panel to
clearly demonstrate the qualitative localization of each protein.
To quantify the spindle pole accumulation frequency of
dynein heavy chain, each replicate included 100 cells for each
condition. The percentage of mitotic cells with clear, strong
foci of the dynein-GFP signal on the spindle poles was
denoted. 3-4 biological replicates were analysed for each con-
dition and the mean percentage of cells (+s.d.) with strong
dynein signal for those replicates was plotted. For ZW10
andMAD1, 2 biological replicates were analysed for each con-
dition and the mean percentage of cells (+s.d.) with spindle
pole-localized signal for those replicates was plotted.
Line scans were generated through the ‘Plot profile’ function
in IMAGEJ, using maximally projected, but not deconvolved,
images.Data accessibility. This article has no additional data.
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